| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | -1241813.64% | -344986.32% | -138044.86% | -664.58% | — | — | — |
| EBITDA Margin | — | -1179818.18% | -330038.95% | -132160.08% | -637.30% | — | — | — |
| Net Margin | — | -1170863.64% | -344489.47% | -136885.60% | -667.74% | — | — | — |
| Current Ratio | 7.93 | 8.54 | 12.38 | 9.70 | 9.78 | 8.96 | 16.46 | 15.89 |
| Quick Ratio | 7.93 | 8.54 | 12.38 | 9.70 | 9.78 | 8.96 | 16.46 | 15.89 |
| Debt / Equity | — | — | — | — | — | — | — | — |
| ROE | -65.25% | -61.01% | -63.89% | -49.95% | -28.04% | -23.18% | -29.35% | -30.08% |
| ROA | -45.90% | -46.94% | -50.91% | -40.71% | -24.74% | -20.38% | -25.72% | -27.33% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | — |
| Book Value / Share | 1.33 | 2.17 | 3.26 | 4.65 | 6.75 | 8.97 | 6.22 | — |
Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. These 'off-the-shelf' products aim to provide faster, more reliable, and scalable cell therapy options compared to autologous approaches, leveraging healthy donor T cells engineered with multiplex gene-editing and proprietary lymphodepletion technologies. Key programs include cemacabtagene ansegedleucel (cema-cel) for frontline large B-cell lymphoma, ALLO-316 targeting clear cell renal cell carcinoma, and ALLO-329 for autoimmune conditions, with ongoing pivotal Phase 2 trials like ALPHA3 and RESOLUTION. Allogene Therapeutics Inc. maintains state-of-the-art in-house manufacturing and collaborates with partners such as Cellectis, Servier, and Arbor Biotechnologies to advance its pipeline. Headquartered in South San Francisco, California, the company operates a fully integrated platform from discovery through development, positioning it as a leader in redefining cell therapy accessibility for blood cancers, solid tumors, and autoimmune disorders.